Alteogen Establishes Biosimilar Subsidiary Altos Biologics
[Asia Economy Reporter Seo So-jeong] Alteogen (CEO Park Soon-jae) announced on the 9th that it has established Altos Biologics, a specialized subsidiary for the development and marketing of biosimilars (biopharmaceutical generics).
Altos Biologics plans to hire experts capable of conducting global clinical trials professionally and will primarily conduct the global Phase 3 clinical trial of Alteogen's macular degeneration treatment biosimilar 'Ailia' ALT-L9.
The interim CEO is Alteogen CEO Park Soon-jae, and the company plans to recruit new global clinical experts soon.
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- "Over 7,000 Residents Evacuate Urgently" Magnitude 5.2 Earthquake Leaves 2 Dead, 6 Injured... What Happened in China?
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
An Alteogen official stated, "Through the establishment of Altos Biologics, we will accelerate global development not only of the Ailia biosimilar but also of differentiated subcutaneous biosimilar products using human hyaluronidase owned by Alteogen, setting us apart from other biosimilar companies."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
